研究揭示一种抗真菌药如何对抗蝙蝠呼肠孤病毒

Core Insights - Researchers at Nagoya University have discovered the mechanism by which the antifungal drug Micafungin acts against the bat-derived Porcine Respiratory Virus (PRV), which is significant for addressing disease transmission related to PRV [1][2] Group 1: Research Findings - PRV was first identified in 1968 in bat species and is known to cause acute respiratory diseases in humans, representing a zoonotic pathogen [1] - Micafungin was found to effectively resist PRV, but its specific mechanism of action was previously unclear [1] - The research team identified that Micafungin binds most strongly to the p17 protein of PRV, which is crucial for its function [1] - The addition of Micafungin to PRV-infected human cells resulted in increased expression of genes associated with the interleukin-6 molecular pathway [1] - The use of synthesized p17 antibodies also led to increased expression of the same gene group, indicating a direct relationship between Micafungin and the p17 protein [1] - Suppressing interleukin-6 gene expression with small interfering RNA (siRNA) promoted the formation of syncytia and increased viral particle release [1] - The study concludes that Micafungin inhibits PRV function through its interaction with the p17 protein and the interleukin-6 molecular pathway [1] Group 2: Implications - Micafungin is already approved as a prescription drug in many regions globally, and the findings from this research could aid in managing potential outbreaks of PRV-related infectious diseases in the future [2]